Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22718494 | 0.90 | P2RX3 (0.47) | P2RX3HDAC1HDAC6ALDH1A1TP53 | |
| SCHEMBL22845499 | 0.82 | NR1H2 (0.43) | P2RX3MAPK1 | |
| SCHEMBL22845402 | 0.79 | P2RX3 (0.43) | P2RX3HDAC1HDAC6TP53 | |
| SCHEMBL22717352 | 0.79 | CLPP (0.46) | HDAC1HDAC6TP53 | |
| SCHEMBL13249772 | 0.77 | P2RX3 (0.49) | P2RX3HDAC1HDAC6OPRD1OPRK1 | |
| SCHEMBL24914777 | 0.76 | ENPP2 (0.54) | P2RX3HDAC1HDAC6ENPP2 | |
| SCHEMBL6421345 | 0.75 | HDAC1 (0.67) | HDAC1HDAC6 | |
| SCHEMBL22717413 | 0.74 | KDM1A (0.47) | P2RX3HDAC1HDAC6ALDH1A1TP53 | |
| SCHEMBL22830643 | 0.74 | MAPT (0.44) | HDAC1HDAC6TP53LMNASMN1; SMN2 | |
| SCHEMBL29676939 | 0.74 | MAPT (0.44) | HDAC1HDAC6TP53LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | P2RX3 3237/4885HDAC1 47/4885HDAC6 12/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | P2RX3 3237/4885HDAC1 47/4885HDAC6 12/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | P2RX3 3237/4885HDAC1 47/4885HDAC6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.